- Eli Lilly received expanded FDA approval for Jaypirca, allowing its first-line use in adults with previously untreated CLL or SLL without a known 17p deletion.
- The approval adds another potential growth driver to Eli Lilly's oncology portfolio, diversifying its future revenue mix alongside its dominant incretin and diabetes franchises.
- Analysts project substantial revenue and earnings growth for Eli Lilly by 2029, though opinions vary on the impact of GLP-1 risks versus oncology opportunities.
Quotes
“This approval adds another potential growth driver to Eli Lilly's oncology portfolio, diversifying its future revenue mix alongside its dominant incretin and diabetes franchises”
“Eli Lilly received expanded FDA approval for Jaypirca, allowing its first-line use in adults with previously untreated CLL or SLL without a known 17p deletion, based on the Phase 3 BRUIN CLL-313 trial”